Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).

被引：0
|
作者：
Gleeson, Jack Patrick
Alhusaini, Abdullah
O'Halloran, Philip
Harrold, Emily
Keegan, Niamh M.
Karadawi, Nabeeha Eltag
Mammadov, Emin
Kamel, Dalia
Egan, Keith
Molloy, Susan
Hennessy, Bryan T.
Breathnach, Oscar S.
Grogan, William
Morris, Patrick G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13515
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first- line treatment of glioblastoma multiforme (GBM)
    Shih, K. C.
    Spigel, D. R.
    Burris, H. A., III
    Brown, R. H.
    Shepard, G. C.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM).
    Gorlia, T
    Stupp, R
    Eisenhauer, EA
    Mirimanoff, RO
    Van Den Bent, MJ
    Belanger, K
    Lacombe, D
    Allgeier, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 859S - 859S
  • [33] RESPONSE OF PROGRESSIVE PEDIATRIC BIFRONTAL GLIOBLASTOMA MULTIFORME TO A COMBINATION OF TARGETED THERAPY USING TEMSIROLIMUS AND BEVACIZUMAB
    Pearlman, Michael L.
    Sadighi, Zsila
    Bingham, Rachel
    Vats, Trib
    Khatua, Soumen
    NEURO-ONCOLOGY, 2011, 13 : 96 - 97
  • [34] PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2012, 14 : 79 - 79
  • [35] Bevacizumab (B) plus irinotecan (I) in progressive multiple pretreated and temozolomide (T) refractory glioblastoma multiforme (GBM): A single center experience using a low dose regimen
    Dresemann, A.
    Hobbold, A.
    Dresemann, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics
    Chamarthy, Sahiti
    Mekala, Janaki Ramaiah
    METABOLIC BRAIN DISEASE, 2023, 38 (05) : 1441 - 1469
  • [37] Use of tissue microarrays (TMA) in evaluating prognostic factors in 100 glioblastoma multiforme (GBM) patients
    Chiesa-Vottero, AG
    Prayson, RA
    Castilla, EA
    Hartke, M
    Rybicki, LA
    Tubbs, RR
    Vogelbaum, M
    Barnett, G
    LABORATORY INVESTIGATION, 2003, 83 (01) : 289A - 289A
  • [38] A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).
    Shih, Kent C.
    Chowdhary, Sajeel A.
    Becker, Kevin P.
    Baehring, Joachim M.
    Liggett, William H.
    Burris, Howard A.
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Use of tissue microarrays (TMA) in evaluating prognostic factors in 100 glioblastoma multiforme (GBM) patients
    Chiesa-Vottero, AG
    Prayson, RA
    Castilla, EA
    Hartke, M
    Rybicki, LA
    Tubbs, RR
    Vogelbaum, M
    Barnett, G
    MODERN PATHOLOGY, 2003, 16 (01) : 289A - 289A
  • [40] Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics
    Sahiti Chamarthy
    Janaki Ramaiah Mekala
    Metabolic Brain Disease, 2023, 38 : 1441 - 1469
12345